Search

Your search keyword '"Yatsuhashi H"' showing total 426 results

Search Constraints

Start Over You searched for: Author "Yatsuhashi H" Remove constraint Author: "Yatsuhashi H"
426 results on '"Yatsuhashi H"'

Search Results

1. An open-label, randomised, controlled trial on the benefit of hmb, L-arginine, and L-glutamine beverages and locomotion training as supportive care in the treatment of unresectable advanced hepatocellular carcinoma using lenvatinib: Hello study

2. Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055))

4. Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055))

5. X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis

6. An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs

8. Hepatitis B Core-Related Antigen to Indicate High Viral Load: Systematic Review and Meta-Analysis of 10,397 Individual Participants

9. X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis

11. Session 08 Germination and dormancy

19. Whole genome viral sequencing reveals subgenotype specific dynamics of antiviral treatment response in HBeAg positive and treatment naive chronic hepatitis B patients

23. Low incidence of hepatitis B virus reactivation and subsequent hepatitis in patients with chronic hepatitis C receiving direct‐acting antiviral therapy

24. Sustained virologic response by ledipasvir/sofosbuvir reduces the incidence of hepatocellular carcinoma in Japanese patients with HCV genotype 1 infection. - Comparison with Simeprevir with peginterferon plus ribavirin

25. Continued improvement in renal laboratory parameters in CHB patients treated with tenofovir alfenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) over 96 weeks

30. Low incidence of hepatitis B virus reactivation and subsequent hepatitis in patients with chronic hepatitis C receiving direct‐acting antiviral therapy.

31. P0786 : 100% SVR12 with ledipasvir/sofosbuvir±ribavirin for 12 weeks in Japanese patients with chronic genotype 1 hepatitis C virus who previously failed therapy with protease inhibitor + pegylated interferonα + ribavirin

33. PS-036 - Sustained virologic response by ledipasvir/sofosbuvir reduces the incidence of hepatocellular carcinoma in Japanese patients with HCV genotype 1 infection. - Comparison with Simeprevir with peginterferon plus ribavirin

34. P1118 NO EFFECT OF FALDAPREVIR ON RENAL FUNCTION IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION: POOLED DATA FROM TWO PHASE III TRIALS

36. P663 IMPACT OF HEPATIC FLARE ON THE LONG-TERM DECLINE IN HEPATITIS B SURFACE ANTIGEN TOWARD ITS SEROCLEARANCE IN CHRONIC HBV CARRIERS: A SINGLE CENTER RETROSPECTIVE ANALYSIS

37. P1132 PHARMACOKINETIC-RESPONSE ANALYSIS OF FALDAPREVIR IN PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION WITH PRIOR RELAPSE

40. ITPA genetic variants influence efficacy of PEG‐IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type

41. 939 WHO MAY HAVE TREATMENT BENEFITS WITH FIBRATES IN PRIMARY BILIARY CIRRHOSIS: A SINGLE CENTER RETROSPECTIVE OBSERVATIONAL COHORT ANALYSIS

43. Measurement of hepatitis B virus core-related antigen is valuable for identifying patients who are at low risk of lamivudine resistance

45. The rs8099917 Polymorphism, When Determined by a Suitable Genotyping Method, Is a Better Predictor for Response to Pegylated Alpha Interferon/Ribavirin Therapy in Japanese Patients than Other Single Nucleotide Polymorphisms Associated with Interleukin-28B

46. 1305 POSITIVE ANTI-GP210 ANTIBODIES IS A RISK FACTOR FOR POOR BIOCHEMICAL RESPONSE TO URSODEOXYCHOLIC ACID TREATMENT IN JAPANESE PATIENTS WITH PRIMARY BILIARY CIRRHOSIS

47. 393 CHANGING OF GENOTYPES AND MOLECULAR EPIDEMIOLOGY OF SPREADING SUBGENOTYPE AE OF HEPATITIS B VIRUS AMONG PATIENTS WITH ACUTE HEPATITIS B IN JAPAN

48. 426 PRETREATMENT SERUM IP-10 IS ASSOCIATED WITH THE FIRST PHASE DECLINE OF HCV-RNA AND OUTCOME OF THERAPY IN CHRONIC HEPATITIS C

50. 469 ITPA GENE VARIANT PROTECTS AGAINST TREATMENT-INDUCED ANEMIA AND IMPROVES VIRAL CLEARANCE BY PEGYLATED INTERFERON-ALFA AND RIBAVIRIN THERAPY IN CHRONIC HEPATITIS C PATIENTS

Catalog

Books, media, physical & digital resources